Adisan Biotechnologies Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 26-06-2024
- Paid Up Capital ₹ 1.50 M
as on 26-06-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.20 Cr
as on 26-06-2024
- Revenue -98.65%
(FY 2022)
- Profit -122.66%
(FY 2022)
- Ebitda -100.76%
(FY 2022)
- Net Worth -13.36%
(FY 2022)
- Total Assets -87.77%
(FY 2022)
About Adisan Biotechnologies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company has closed loans amounting to ₹2.20 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Suvarnarekha Devadhar and Aditya Devadhar serve as directors at the Company.
- CIN/LLPIN
U24239PN2012PTC144248
- Company No.
144248
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Adisan Biotechnologies Private Limited offer?
Adisan Biotechnologies Private Limited offers a wide range of products and services, including Animal Medicines & Health Care, Veterinary Medicines, Insecticides and Pesticides, Pest Control Chemicals, Deltamethrin, Soaps, Detergent Powder & Cakes, Detergent, Acaricide, Insecticides, Cypermethrin.
Who are the key members and board of directors at Adisan Biotechnologies?
Board Members(2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Suvarnarekha Devadhar | Director | 30-Dec-2014 | Current |
Aditya Devadhar | Director | 01-Aug-2012 | Current |
Financial Performance of Adisan Biotechnologies.
Adisan Biotechnologies Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 98.65% decrease. The company also saw a substantial fall in profitability, with a 122.66% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations | |||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Adisan Biotechnologies?
In 2021, Adisan Biotechnologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Adisan Laboratories Private LimitedActive 14 years
Suvarnarekha Devadhar and Aditya Devadhar are mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
The Federal Bank Ltd Creation Date: 08 Jan 2016 | ₹9.40 M | Satisfied |
The Federal Bank Ltd Creation Date: 08 Jan 2016 | ₹1.26 Cr | Satisfied |
How Many Employees Work at Adisan Biotechnologies?
Unlock and access historical data on people associated with Adisan Biotechnologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adisan Biotechnologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adisan Biotechnologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.